GlassScriptPhysician profile
Karol Rivera
NPI 1902218571
$2,592.84
in general payments reported to CMS, 2019-2025
27 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.99 · 2022: $496 · 2023: $649 · 2024: $52.32 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,600 · Travel and Lodging: $412 · Entertainment: $10.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,600.48 |
| Travel and Lodging | $412.05 |
| Entertainment | $10.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $486.61 | 2024-2025 | |
| Medtronic, INC. | $434.91 | 2025 | Closurefast, Truclear |
| Abbvie INC. | $308.30 | 2021-2023 | |
| Astellas Pharma US INC | $239.38 | 2023-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $162.14 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.31 | 2021-2023 | |
| Exeltis, USA INC. | $98.06 | 2022-2025 | Slynd |
| Daiichi Sankyo INC. | $74.63 | 2025 | Injectafer |
| Pacira Pharmaceuticals Incorporated | $72.82 | 2023-2025 | Exparel, Iovera |
| Hologic Sales and Service, LLC | $67.12 | 2024-2025 | Aptima, Myosure Tissue Removal Device, Novasure |
| Organon LLC | $65.34 | 2022-2025 | Nexplanon |
| Novo Nordisk INC | $61.33 | 2022-2023 | Wegovy |
| Exact Sciences Corporation | $50.98 | 2025 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $50.11 | 2022-2025 | Phexxi, Solosec, Phexx |
| Sumitomo Pharma America, INC. | $48.13 | 2023-2024 | Myfembree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36.13 | 2022-2023 | |
| Baxter Healthcare | $26.54 | 2025 | Perclot |
| Mycovia Pharmaceuticals, INC. | $25.33 | 2023 | Vivjoa |
| Dexcom, INC. | $21.51 | 2025 | Dexcom G6 Transmitter |
| Myovant Sciences INC. | $21.05 | 2022 | |
| Merck Sharp & Dohme LLC | $18.12 | 2022 | |
| Shield Therapeutics INC | $15.39 | 2023 | Accrufer |
| Lilly USA, LLC | $15.33 | 2022 | |
| Amgen INC. | $14.46 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.51 | 2022 | |
| Agile Therapeutics, INC. | $12.98 | 2022 | |
| Argentum Medical | $10.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karol Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.